IMAX Adds Three India Locations, But Thesis Remains Unchanged

What happened

IMAX announced a deal with Asian Cinemas to open three new IMAX with Laser locations in India under the AMB Cinemas brand, two in Hyderabad and one elsewhere, with the first opening by end of 2026. While this extends IMAX's footprint in a fast-growing market, it represents a negligible addition to the company's 1,829-system base and 478-system backlog. The investment thesis remains cautious: the stock trades at ~48x trailing EPS and ~18x EV/EBITDA, pricing in sustained record box office that is highly sensitive to a handful of tentpoles and China exposure. India expansion is positive but too small to move the needle on earnings or reduce the cyclical risks flagged in the latest filings. As such, the deal does not alter the view that IMAX offers limited upside from current levels with a skew toward downside.

Implication

Investors should view this as incremental evidence of international growth, but it fails to mitigate the key risks: a 48x P/E, reliance on the 2026 slate hitting ~$1.4B box office, and heavy China exposure. The bear case (value ~$24) remains plausible if box office disappoints or China stumbles. Holders should look to trim on strength; new buyers wait for a better entry below $30.

Thesis delta

This India deal is consistent with IMAX's reported international expansion but does not change the fundamental risk/reward. The potential sell rating is reaffirmed because the news does not reduce the reliance on a perfect 2026 slate or the vulnerability to China and cyclical box office. The bullish narrative of structural growth is already priced in, leaving no margin of safety at current levels.